(TDOC) Teladoc - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US87918A1051
TDOC: Virtual, Medical, Therapy, Counseling, Healthcare, Services
Teladoc Health, Inc. (NYSE: TDOC) is a global leader in delivering virtual healthcare services, operating through two core segments: Teladoc Health Integrated Care and BetterHelp. The Integrated Care segment provides a comprehensive suite of virtual medical services, including general and expert medical care, specialty consultations, chronic condition management, and mental health support. Additionally, it offers enabling technologies and enterprise telehealth solutions tailored for hospitals and health systems. This segment essentially bridges the gap between patients and healthcare providers through digital platforms, ensuring access to care regardless of physical location.
The BetterHelp segment focuses exclusively on mental health, operating a platform that connects individuals with licensed clinicians for counseling and therapy. Services are accessible via website, mobile apps, phone calls, and text-based interactions, making mental health support more accessible and convenient. Teladoc Health serves a diverse range of customers, including employers, health plans, hospitals, insurance companies, and individual members. The company, rebranded from Teladoc, Inc. in 2018, was founded in 2002 and is headquartered in Purchase, New York. Its product offerings are delivered under the Teladoc, Livongo, and BetterHelp brands.
From a financial perspective, Teladoc Health has a market capitalization of approximately $2.3 billion, placing it in the mid-cap category. The company currently operates at a negative trailing P/E ratio, indicating operating losses, though its forward P/E ratio of 357.14 reflects investor expectations of significant future earnings growth. The price-to-book (P/B) ratio of 1.54 suggests that the market values the company slightly above its book value, while the price-to-sales (P/S) ratio of 0.90 indicates a reasonable valuation relative to its revenue. These metrics are critical for investors and fund managers assessing the companys growth potential and valuation in the rapidly evolving telehealth industry.
Additional Sources for TDOC Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
TDOC Stock Overview
Market Cap in USD | 1,631m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception | 2015-07-01 |
TDOC Stock Ratings
Growth 5y | -83.7% |
Fundamental | -12.7% |
Dividend | 0.0% |
Rel. Strength Industry | -42.4 |
Analysts | 3.36/5 |
Fair Price Momentum | 5.23 USD |
Fair Price DCF | 22.57 USD |
TDOC Dividends
No Dividends PaidTDOC Growth Ratios
Growth Correlation 3m | 0.3% |
Growth Correlation 12m | -34.3% |
Growth Correlation 5y | -97% |
CAGR 5y | -40.57% |
CAGR/Max DD 5y | -0.42 |
Sharpe Ratio 12m | -0.92 |
Alpha | -53.76 |
Beta | 1.18 |
Volatility | 66.91% |
Current Volume | 4798.2k |
Average Volume 20d | 8390.8k |
As of March 15, 2025, the stock is trading at USD 8.62 with a total of 4,798,246 shares traded.
Over the past week, the price has changed by -5.79%, over one month by -39.85%, over three months by -19.29% and over the past year by -41.91%.
Neither. Based on ValueRay Fundamental Analyses, Teladoc is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -12.67 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TDOC as of March 2025 is 5.23. This means that TDOC is currently overvalued and has a potential downside of -39.33%.
Teladoc has received a consensus analysts rating of 3.36. Therefor, it is recommend to hold TDOC.
- Strong Buy: 3
- Buy: 3
- Hold: 19
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, TDOC Teladoc will be worth about 5.7 in March 2026. The stock is currently trading at 8.62. This means that the stock has a potential downside of -34.45%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 10.9 | 26.3% |
Analysts Target Price | 11 | 27% |
ValueRay Target Price | 5.7 | -34.5% |